ArticleKorean journal of clinical oncology2026
Follow-up for patients with extremity soft tissue sarcoma: validation of a rational schedule.
Article in Korean journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePatients with soft tissue sarcomas (STS) of the extremity require ongoing follow-up to detect treatment failures. There is a significant variation in follow-up schemes among sarcoma specialists due to a lack of evidence.
methodsA retrospective single-center review was performed on all patients with a minimum 1-year follow-up after resection of a localized STS, utilizing a prospectively collected database. Kaplan-Meier curves were used to calculate the incidence of local recurrence and metastases on an annual basis over 10 years.
resultsThere were 407 patients who met the inclusion criteria. Considering the annual incidence of local recurrence and distant metastasis per STS size and grade, patients with small, low-grade STS should be followed yearly for 10 years. Patients with small, intermediate/high-grade STS and those with large, low-grade STS should be followed every 6 months for the first 2 years and then yearly until 10 years postoperatively. Patients with large, intermediate/high-grade STS should be followed every 3 months for the first 2 years and then every 6 months thereafter until 10 years postoperatively.
conclusionCompared to National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) guidelines, our proposed scheme has the potential to reduce hospital visits, mainly for patients with small intermediate and high-grade tumors. This protocol validates the previously published scheme, despite being relatively more conservative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.